Incyte Corporation (INCY) : Tuesdays money flow points at investors jumping to buy the stock on the weakness of price. $20.27 million worth of transactions were on upticks, whereas, the downticks accounted for $16.14 million worth of transactions. The net money flow was a positive $4.14 million and the uptick to downtick ratio was 1.26. The net money flow into the stock was $4.11 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $4.11 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Incyte Corporation (INCY) was trading at $85, down $0.7 during day. The stock slid -0.82% over the previous days close. For the week, the stock recorded 4.59% over the previous weeks close.
The company Insiders own 13.7% of Incyte Corporation shares according to the proxy statements. Institutional Investors own 95.83% of Incyte Corporation shares. In an insider trading activity, Swain Paula J, officer (EVP, Human Resources) of Incyte Corp, unloaded 13,531 shares at an average price of $76.96 on January 15, 2016. The total amount of the transaction was worth $1,041,346, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Shares of Incyte Corporation rose by 6.6% in the last five trading days and 5.67% for the last 4 weeks. Incyte Corporation is up 9.82% in the last 3-month period. Year-to-Date the stock performance stands at -21.65%.
Incyte Corporation (NASDAQ:INCY): On Tuesdays trading session , Opening price of the stock was $85.63 with an intraday high of $86.11. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $84.9. However, the stock managed to close at $84.97, a loss of 0.04% for the day. On the previous day, the stock had closed at $85. The total traded volume of the day was 594,028 shares.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f